This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS

This study has been completed.
Information provided by:
Hospital Universitario Ramon y Cajal Identifier:
First received: January 29, 2007
Last updated: January 30, 2007
Last verified: January 2007

Cardiovascular risk factors cluster in hyperandrogenic women - including those presenting with the polycystic ovary syndrome - in association with insulin resistance, obesity, and other metabolic disorders.

The present clinical trial intends to compare the effects of oral contraceptives and metformin on PCOS patients, focusing on classic and non-classic cardiovascular risk markers and indexes of cardiovascular performance, in order to whether or not, as suspected by previous data obtained in non-hyperandrogenic women, oral contraceptives worsen the cardiovascular risk profile of PCOS women, favoring the use of metformin if the latter actually ameliorates such a risk.

Condition Intervention Phase
Polycystic Ovary Syndrome Drug: Metformin Drug: Ethynyl-estradiol plus cyproterone acetate Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives

Resource links provided by NLM:

Further study details as provided by Hospital Universitario Ramon y Cajal:

Primary Outcome Measures:
  • Serum androgen levels
  • Lipid profiles
  • Blood pressure
  • Cardiovascular performance
  • Non-classic cardiovascular risk markers
  • Indexes of insulin secretion and sensitivity

Estimated Enrollment: 50
Study Start Date: April 2004
Estimated Study Completion Date: October 2006

Ages Eligible for Study:   12 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women of fertile age presenting with PCOS
  • Non-hyperandrogenic women of fertile age (these women will not receive the interventions and will serve only to obtain normative data for some variables)

Exclusion Criteria:

  • Severe disease not related to the condition under study
  • Pregnancy
  • Medical or surgical treatment of PCOS during the previous 3 months
  • Contraindication for the use of oral contraceptives or metformin
  • Inability to understand the proposal of the study precluding effective informed consent
  • Minors who are not accompanied by their legal representative
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00428311

Department of Endocrinology, Hospital Ramón y Cajal
Madrid, Spain, E-28034
Sponsors and Collaborators
Hospital Universitario Ramon y Cajal
Principal Investigator: Héctor F Escobar-Morreale, MD, PhD Hospital Universitario Ramón y Cajal
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00428311     History of Changes
Other Study ID Numbers: ENDOPCOS 01/2003
Study First Received: January 29, 2007
Last Updated: January 30, 2007

Keywords provided by Hospital Universitario Ramon y Cajal:
Polycystic ovary syndrome
Cardiovascular risk
Chronic inflammation
Cyproterone acetate
Oral contraceptives

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
46, XX Disorders of Sex Development
Disorders of Sex Development
Urogenital Abnormalities
Adrenogenital Syndrome
Congenital Abnormalities
Ethinyl Estradiol
Contraceptive Agents
Cyproterone Acetate
Contraceptives, Oral
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 21, 2017